ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
6.01
-0.65 (-9.76%)
At close: May 12, 2025, 4:00 PM
6.01
0.00 (0.00%)
After-hours: May 12, 2025, 7:48 PM EDT
ReShape Lifesciences Revenue
In the year 2024, ReShape Lifesciences had annual revenue of $8.01M, down -7.74%. ReShape Lifesciences had revenue of $1.81M in the quarter ending December 31, 2024, a decrease of -8.93%.
Revenue (ttm)
$8.01M
Revenue Growth
-7.74%
P/S Ratio
0.02
Revenue / Employee
$444,778
Employees
18
Market Cap
2.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.01M | -672.00K | -7.74% |
Dec 31, 2023 | 8.68M | -2.56M | -22.79% |
Dec 31, 2022 | 11.24M | -2.36M | -17.35% |
Dec 31, 2021 | 13.60M | 2.30M | 20.36% |
Dec 31, 2020 | 11.30M | -3.79M | -25.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RSLS News
- 14 hours ago - Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 5 days ago - ReShape Lifesciences Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 10 days ago - ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium - GlobeNewsWire
- 14 days ago - ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - GlobeNewsWire
- 21 days ago - ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - GlobeNewsWire
- 4 weeks ago - ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript) - Seeking Alpha
- 4 weeks ago - ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market - GlobeNewsWire
- 5 weeks ago - ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - GlobeNewsWire